EMCUREEmcure Pharmaceuticals Ltd.

    Emcure Pharmaceuticals Ltd: results and news

    Every Emcure Pharmaceuticals Ltd filing with the NSE and BSE that Blacklitt has written about, explained in plain words and linked to the filing, newest first: earnings, mergers & acquisitions.

    2 articles · pharmaceuticals · Latest 3 Nov 2026

    Two empty glass test tubes lying side by side on a plain grey surface, with a few dark specks in one tube.

    EMCUREEmcure Pharmaceuticals Ltd.

    Emcure Pharmaceuticals Q2 FY27 Results: Consolidated Net Profit ₹325 Crore on Total Income of ₹2,824 Crore

    Emcure Pharmaceuticals (NSE: EMCURE) reported consolidated total income of ₹2,823.73 crore and net profit of ₹325.07 crore for the quarter ended 30 Sep 2026, it said in a filing on 03 Nov 2026. Standalone total income was ₹1,701.52 crore and standalone net profit ₹248.43 crore for the same quarter.

    • Earnings
    • pharmaceuticals

    Blacklitt Research4 min read

    EMCUREEmcure Pharmaceuticals Ltd

    Emcure Pharmaceuticals’ board approves merging subsidiaries Zuventus Healthcare and Emcutix Biopharmaceuticals into the company

    Emcure Pharmaceuticals Limited has told the exchanges that its board, at a meeting on 12 Oct 2026 that ran from 9:45 AM to 10:10 AM, approved a draft composite scheme of amalgamation. Under it, two wholly owned subsidiaries, Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited, would merge into Emcure Pharmaceuticals Limited, with their respective shareholders and creditors included, under Sections 230 to 232 of the Companies Act, 2013.

    • Mergers & acquisitions
    • Pharmaceuticals

    Blacklitt Research2 min read